GSK India Chief On Pandemic Decisions, Refreshing The Portfolio
GSK India managing director Sridhar Venkatesh outlines how the company navigated pandemic-related turbulence and “stuck its neck out” to ensure uninterrupted supplies of key drugs. The executive also discusses launch prospects for products including Xevudy in India and an intent to “refresh” the company’s vaccines portfolio.
You may also be interested in...
HPV Vaccines – The Journey So Far And Long Road Ahead
HPV vaccines have come a long way since their launch in 2006, though not without their share of bumps and misinformation campaigns. US pediatric infectious disease specialist, Dr Kenneth Alexander, talks to Scrip about how data has evolved, why the US may not be the best example to emulate for HPV vaccination and new products on the horizon, among other topics.
CEO Pay Mostly Up In India In Year Of C-Suite Exits
Most CEOs/MDs at leading listed foreign and domestic drug firms in India took home bigger pay packages in 2021-22, a period that also saw several top-level exits including at Abbott, Pfizer and Sanofi. Scrip examines some of the wider trends around executive compensation.
Big Pharma Restructures Commercial Teams In India
More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.